Eli Lilly Projects 2026 Revenue Between $91B and $92B Amid GLP-1 Expansion
Eli Lilly (LLY) has provided a robust long-term financial outlook, projecting annual revenue of $91 billion to $92 billion for the year 2026. This growth is expected to be driven by the expansion of access to its GLP-1 medications through initiatives like the Medicare GLP-1 Bridge and the rollout of Foundayo. CEO David Ricks highlighted the company's strong execution during the recent quarter, noting that Lilly has raised its full-year financial guidance. The company is currently focused on advancing its drug pipeline and significantly expanding its manufacturing footprint to meet increasing global demand for its metabolic and weight-loss treatments.
Tickers: $LLY
Topics: earnings report financial guidance manufacturing expansion pipeline advancement